Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC = 50%) and Without Actionable Genomic Alterations

Active:	Yes
Cancer Type:	Lung Cancer Unknown Primary	NCT ID:	NCT06357533
Trial Phases:	Phase III	Protocol IDs:	D7632C00001 (primary) NCI-2024-07729 2023-505077-32-00
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	AstraZeneca Pharmaceuticals LP
NCI Full Details:	http://clinicaltrials.gov/show/NCT06357533

Summary

The purpose of this study is to evaluate efficacy and safety of Dato-DXd in combination
with rilvegostomig or rilvegostomig monotherapy compared with pembrolizumab monotherapy
as a first line therapy in participants with locally advanced or metastatic non-squamous
NSCLC with high PD-L1 expression (TC = 50%) and without actionable genomic alterations.

Objectives

This is a Phase III, randomized, open-label, Global Study of Datopotamab Deruxtecan
(Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig monotherapy versus
Pembrolizumab monotherapy for the first-line treatment of participants with
locally-advanced or metastatic non-squamous NSCLC with high PD-L1 expression (TC = 50%)
and without actionable genomic alterations.

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.